ALMA observations of polarized emission toward the CW Tau and DG Tau protoplanetary disks: constraints on dust grain growth and settling

We present polarimetric data of CW Tau and DG Tau, two well-known Class II disk/jet systems, obtained with the Atacama Large Millimeter/submillimeter Array at 870 $\mu$m and 0."2 average resolution. In CW Tau, the total and polarized emission are both smooth and symmetric, with polarization angles almost parallel to the minor axis of the projected disk. In contrast, DG Tau displays a structured polarized emission, with an elongated brighter region in the disk's near side and a belt-like feature beyond about 0."3 from the source. At the same time the total intensity is spatially smooth, with no features. The polarization pattern, almost parallel to the minor axis in the inner region, becomes azimuthal in the outer belt, possibly because of a drop in optical depth. The polarization fraction has average values of 1.2% in CW Tau and 0.4% in DG Tau. Our results are consistent with polarization from self-scattering of the dust thermal emission. Under this hypothesis, the maximum size of the grains contributing to polarization is in the range 100 - 150 $\mu$m for CW Tau and 50 - 70 $\mu$m for DG Tau. The polarization maps combined with dust opacity estimates indicate that these grains are distributed in a geometrically thin layer in CW Tau, representing a settling in the disk midplane. Meanwhile, such settling is not yet apparent for DG Tau. These results advocate polarization studies as a fundamental complement to total emission observations, in investigations of the structure and the evolution of protoplanetary disks.Comment: 8 pages, 5 figures. Accepted for publication in ApJ Letter

PRISM (Polarized Radiation Imaging and Spectroscopy Mission): A White Paper on the Ultimate Polarimetric Spectro-Imaging of the Microwave and Far-Infrared Sky

PRISM (Polarized Radiation Imaging and Spectroscopy Mission) was proposed to ESA in response to the Call for White Papers for the definition of the L2 and L3 Missions in the ESA Science Programme. PRISM would have two instruments: (1) an imager with a 3.5m mirror (cooled to 4K for high performance in the far-infrared---that is, in the Wien part of the CMB blackbody spectrum), and (2) an Fourier Transform Spectrometer (FTS) somewhat like the COBE FIRAS instrument but over three orders of magnitude more sensitive. Highlights of the new science (beyond the obvious target of B-modes from gravity waves generated during inflation) made possible by these two instruments working in tandem include: (1) the ultimate galaxy cluster survey gathering 10e6 clusters extending to large redshift and measuring their peculiar velocities and temperatures (through the kSZ effect and relativistic corrections to the classic y-distortion spectrum, respectively) (2) a detailed investigation into the nature of the cosmic infrared background (CIB) consisting of at present unresolved dusty high-z galaxies, where most of the star formation in the universe took place, (3) searching for distortions from the perfect CMB blackbody spectrum, which will probe a large number of otherwise inaccessible effects (e.g., energy release through decaying dark matter, the primordial power spectrum on very small scales where measurements today are impossible due to erasure from Silk damping and contamination from non-linear cascading of power from larger length scales). These are but a few of the highlights of the new science that will be made possible with PRISM.Comment: 20 pages Late

Anatomo-radiological study of the superficial musculo-aponeurotic system of the face.

The aim of the study was to analyse the appearance of the superficial muscolo-aponeurotic system (SMAS) in radiological images (Magnetic Resonance -MR- and Computed tomography -CT- scans, 10M, 10F randomly selected) in the three regions of the face (the parotid and cheek regions and the nasolabial fold). In axial CT images, the SMAS appears as a relatively hyperdense tortuous line between the hypodense superficial fibroadipose tissue (SAT) and the hypodense deep adipose tissue (DAT). In parotid region SAT is well represented (mean thickness 4.32 +/- 2.9 mm), whereas DAT is very thin (0.33 +/- 0.48 mm); SMAS appears as a thin hyperdense line, close to the parotid gland (0.76 +/- 0.43 mm). In cheek region, SAT is well represented (5.57 +/- 1.17 mm), whereas DAT is thinner (2.94 +/- 0.62 mm), and SMAS is well recognisable (1.69 +/- 0.52 mm). At the level of the nasolabial fold, the SAT is poorly represented (0.37 +/- 0.06 mm); the SMAS continues in the mimic muscles (2.41 +/- 0.05 mm), and DAT shows a mean thickness of 2.15 +/- 0.63 mm. In the MR examination, the SMAS appears as a thin continuous line hypointense in the T1-and T2-weighted sequence, from parotid region to nasolabial fold, comprising mimic muscles in the anterior region of the cheek and at the level of the nasolabial fold. No significative differences in thickness between CT and MR were found. Our anatomo-radiological study confirms that the subcutaneous architecture of the face consists of multiple layers of tissues that connect facial muscles with the dermis. This pattern of arrangement shows a progressive centrifugal thinning towards the adjacent regions

PRISM (Polarized Radiation Imaging and Spectroscopy Mission): an extended white paper

Contains fulltext : 126057.pdf (preprint version ) (Open Access

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFIRST was a 12-month retrospective, multicentre study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of seizure response (≥50% reduction in baseline seizure frequency), seizure-freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Results: Patients with PSE included in the BRIVAFIRST were 75 and had a median age of 57 (interquartile range, 42-66) years. The median daily doses of BRV at 3, 6, and 12 months from starting treatment were 100 (100-150) mg, 125 (100-200) mg and 100 (100-200) mg, respectively. At 12 months, 32 (42.7%) patients had a reduction in their baseline seizure frequency by at least 50%, and the seizure freedom rates was 26/75 (34.7%). During the 1-year study period, 10 (13.3%) patients discontinued BRV. The reasons of treatment withdrawal were insufficient efficacy in 6 (8.0%) patients and poor tolerability in 4 (5.3%) patients. Adverse events were reported by 13 (20.3%) patients and were rated as mild in 84.6% and moderate in 15.4% of cases. Significance: Adjunctive BRV was efficacious and generally well-tolerated when used in patients with PSE in clinical practice. Adjunctive BRV can be a suitable therapeutic option for patients with PSE